Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Common Equity: 2022-2025

Historic Common Equity for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $340.7 million.

  • Entrada Therapeutics' Common Equity fell 19.35% to $340.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $340.7 million, marking a year-over-year decrease of 19.35%. This contributed to the annual value of $428.7 million for FY2024, which is 76.88% up from last year.
  • Per Entrada Therapeutics' latest filing, its Common Equity stood at $340.7 million for Q3 2025, which was down 10.22% from $379.5 million recorded in Q2 2025.
  • Entrada Therapeutics' Common Equity's 5-year high stood at $429.9 million during Q2 2024, with a 5-year trough of $206.9 million in Q2 2023.
  • Moreover, its 3-year median value for Common Equity was $340.7 million (2025), whereas its average is $328.5 million.
  • In the last 5 years, Entrada Therapeutics' Common Equity skyrocketed by 107.79% in 2024 and then decreased by 19.35% in 2025.
  • Quarterly analysis of 4 years shows Entrada Therapeutics' Common Equity stood at $212.6 million in 2022, then rose by 14.02% to $242.4 million in 2023, then skyrocketed by 76.88% to $428.7 million in 2024, then decreased by 19.35% to $340.7 million in 2025.
  • Its Common Equity was $340.7 million in Q3 2025, compared to $379.5 million in Q2 2025 and $417.3 million in Q1 2025.